Day: June 23, 2025

$500M facility earmarked for the strategic accumulation of Bitcoin to serve as the Company’s primary reserve asset and for the funding of growth and general corporate purposes. The Company will grow its digital asset footprint beyond the recent BitPay relationship to unlock the crypto-native customer demographic. First 21 customers to purchase a vehicle with Bitcoin to receive $21,000 upgrade credit.KISSIMMEE, Fla. , June 23, 2025 (GLOBE NEWSWIRE) — ECD Automotive Design, Inc. (NASDAQ: ECDA), the world’s largest Land Rover and Jaguar restoration company known for its custom luxury builds, including bespoke Defenders, Range Rovers, Jaguar E-Types, Ford Mustangs and Toyota FJs is thrilled to announce the signing of a $500M equity facility with ECDA Bitcoin Treasury LLC (the “Facility”). The proceeds of this strategic financing...

A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) — Dr Ashleys Limited, a Hong Kong based global pharmaceutical company (“Dr Ashleys”), and Impact BioMedical Inc. (“Impact BioMedical”) (NYSE American: IBO), a Texas based biopharmaceuticals developer listed on the New York Stock Exchange American (“Impact BioMedical”, together with Dr Ashleys, the “Parties”), are pleased to announce the execution of a merger and share exchange agreement (the “Merger Agreement”) on June 21, 2025 to enter into a strategic merger transaction (the “Transaction”). Upon closing of the Transaction, Dr. Ashleys will acquire Impact BioMedical through a reverse merger that will result in a newly formed combined entity (the “PubCo”) traded on the NYSE American under...

Vancouver, Canada, June 23, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the addition of Tel Aviv Sourasky Medical Center (TASMC), Tel Aviv, Israel, as an additional clinical site for its ongoing Phase I/IIa clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This expansion follows the recent enrollment of the first patient in the trial, announced on June 5, 2025, marking a significant milestone in the development of CMND-100. The study at Tel Aviv Sourasky Medical Centerwill be led by Dr. David Zeltser,...

New findings demonstrated that a single dose of Rejuva was well tolerated in healthy animals, with no evidence of toxicity Rejuva-treated healthy animals exposed to a high fat diet were protected from weight gain and hyperglycemia Data reinforce advancement of RJVA-001 toward first-in-human studies; preliminary clinical data expected in 2026 BURLINGTON, Mass., June 23, 2025 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Diabetes Association’s (ADA) 85th Scientific Sessions. The abstract, titled “Single-Dose GLP-1-Based Pancreatic Gene Therapy Prevents Obesity...

12 of 13 participants maintained or lost weight at 3 months, with 6 of 13 losing additional weight after stopping GLP-1 therapy and undergoing Revita procedure Median weight remained stable through 3 months (0.46% / ~ 1 pound weight change within the margin of error for daily weight measurement), compared to expected 5–6% weight regain (10–15 pounds) after stopping GLP-1 therapy Revita continued to demonstrate excellent tolerability profile compared to GLP-1 drugs; treatment-emergent adverse effects were infrequent, mild, and transient Randomized Midpoint Cohort data expected in Q3 2025; Pivotal Cohort data anticipated in H2 2026 BURLINGTON, Mass., June 23, 2025 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root...

MILTON, N.Y., June 23, 2025 (GLOBE NEWSWIRE) — Sono-Tek Corporation (Nasdaq: SOTK), a leading developer of ultrasonic precision coating systems, today announced that it has received a $1.12 million order from a long-standing customer in the medical diagnostic testing industry. The customer, a global manufacturer of medical diagnostic platforms, has partnered with Sono-Tek for nearly a decade, deploying over ten of the company’s mid-size ultrasonic coating systems, typically ranging from $110,000 to $150,000 each. This significantly larger new order represents a major evolution in the relationship, demonstrating Sono-Tek’s enhanced capabilities in advanced automation and high-volume product handling. “This order reflects our customer’s confidence in Sono-Tek’s expanding capabilities and exemplifies our strategy to guide customers...

In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, outperforming the group given semaglutide alone Icovamenib promoted healthy myotube morphology and diminished drug-induced atrophy in ex vivo 3D-engineered human myotube cultures In severely insulin-deficient patients from the Phase II COVALENT-111 trial, icovamenib achieved a 1.0% placebo-adjusted mean HbA1c reduction and a 55% increase in C-peptide at Week 26, three weeks after last doseSAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Biomea or Biomea Fusion) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of new preclinical and clinical data for...